Results 71 to 80 of about 54,430 (257)
Initial manifestations and clinical course of systemic onset juvenile idiopathic arthritis: A ten-year retrospective study [PDF]
, 2014 Background/Purpose: The diagnosis of systemic onset juvenile idiopathic arthritis (SoJIA) on disease onset is challenging and made mainly by exclusion. This study aimed to investigate the initial clinical and laboratory features of children with SoJIA in
王麗潔 ;李志鴻 ;俞欣慧 ;江伯倫 ;楊曜旭 +1 more
core +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Arthritis &Rheumatology, EarlyView.Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
Медицинская иммунология, 2019 Juvenile idiopathic arthritis is a chronic inflammatory disease of the joints in children, mainly of autoimmune or auto-inflammatory nature. It is a heterogeneous group, which includes different subtypes of the disease. Different mechanisms may play role
I. M. Krivolapova +2 more
doaj +1 more source
Arthritis &Rheumatology, Accepted Article.Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner +28 more
wiley +1 more source
Pharmacotherapy of Juvenile Idiopathic Arthritis [PDF]
, 2018 Juvenile idiopathic arthritis (JIA) is a heterogeneous group of paediatric diseases that all have in common the fact that they involve joint inflammation and occur before the age of 16.
Hussain, Ali
core
British Journal of Clinical Pharmacology, EarlyView.Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Maxillary sinusitis and Juvenile Idiopathic Arthritis : A Cone Beam CT study [PDF]
, 2016 AIM: To evaluate a possible correlation between Juvenile Idiopathic Arthritis (JIA) and sinusitis of the maxillary sinuses and determine their prevalence.
C. Batia +6 more
core
Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis [PDF]
, 2016 Pediatric uveitis may be a serious health problem because of the lifetime burden of vision loss due to severe complications if the problem is not adequately treated.
İlknur Tuğal-Tutkun
core +1 more source
THE ROLE OF APOPTOSIS VIOLATIONS IN THE JUVENILE IDIOPATHIC ARTHRITIS FORMATION
Педиатрическая фармакология, 2012 We investigated the polymorphism of the gene p53 exon 4 Arg72Pro and intron 3 ins/del 16 b. p. in children with juvenile idiopathic arthritis in order to identify the influence of gene polymorphisms on the course and outcome of the disease.
A. N. Kozhevnikov +4 more
doaj +1 more source